Prothena Corp (PRTA) 38.17 $PRTA
Prothena Reports Results of Phase 1 Single Ascending Dose Study of PRX003, Demonstrating Target Engagement of the Novel Anti-MCAM Antibody for Inflammatory Diseases
Globe Newswire - Thu Jun 09, 3:05PM CDT
- All doses of PRX003 found to be safe and well tolerated, meeting the primary objective of the Phase 1 single ascending dose study in healthy volunteers
PRTA: 38.17 (-1.03)
Prothena to Present Wide Range of Studies on Amyloidosis, Including New Clinical Data on NEOD001, at International Symposium on Amyloidosis
Globe Newswire - Mon May 23, 3:05PM CDT
- New clinical data to be presented from expansion cohort of Phase 1/2 trial of NEOD001 for the potential treatment of AL amyloidosis
PRTA: 38.17 (-1.03)
Prothena to Present Quality of Life Data on AL Amyloidosis at European Hematology Association 21st Congress
Globe Newswire - Thu May 19, 3:05PM CDT
DUBLIN, Ireland, May 19, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq
RTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that data from multiple quality of life studies in patients with AL amyloidosis will be highlighted at The European Hematology Association (EHA) 21st Congress to be held June 9-12 in Copenhagen, Denmark.
PRTA: 38.17 (-1.03)
Prothena to Present Clinical Results From its Phase 1 Single Ascending Dose Study of PRX003, an Anti-MCAM Antibody Being Investigated for Inflammatory Diseases, at EULAR 2016
Globe Newswire - Mon May 09, 3:05PM CDT
DUBLIN, Ireland, May 09, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NasdaqRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that clinical data from its Phase 1 single ascending dose study of PRX003 in healthy volunteers will be highlighted in an oral presentation at The European League Against Rheumatism Annual European Congress of Rheumatology (EULAR 2016) to be held June 8-11 in London.
PRTA: 38.17 (-1.03)
Prothena (PRTA) Reports Wider-than-Expected Loss in Q1
Zacks Equity Research - Zacks Investment Research - Wed May 04, 12:00PM CDT
Prothena Corporation plc (PRTA) reported a loss of 81 cents per share in the first quarter of 2016, much wider than both the Zacks Consensus Estimate of a loss of 70 cents.
SHPG: 175.38 (+0.76), PRTA: 38.17 (-1.03), NKTR: 15.09 (+0.11)
Prothena Reports First Quarter 2016 Financial Results and Provides R&D Update
Globe Newswire - Tue May 03, 3:05PM CDT
- Net cash used in operating and investing activities was $25.4 million in the first quarter; strong quarter-end cash position of $474.3 million, including net proceeds of $128.6 million raised through January 2016 public equity offering, supports advancement of multiple clinical development programs
PRTA: 38.17 (-1.03)
Drug Stocks Q1 Earnings Preview: AEGR, AERI, MACK, PRTA
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 8:04AM CDT
The going has been quite satisfactory as we stand in the thick of the first earnings season of the year.
MACK: 6.20 (-0.09), BIIB: 234.60 (+1.60), ABT: 38.74 (+1.01), JNJ: 116.46 (+0.28), AERI: 17.56 (-0.02), AEGR: 1.56 (+0.03), PRTA: 38.17 (-1.03)
Prothena (PRTA): What's Ahead for the Stock in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 5:42PM CDT
Prothena (PRTA) is expected to report first-quarter 2016 earnings on May 3.
ZTS: 47.33 (+0.04), AGIO: 47.07 (-0.26), PRTA: 38.17 (-1.03)
Data from Prothena's Preclinical Program on Conformation-Specific Antibodies Against Misfolded Transthyretin Published in Amyloid
Globe Newswire - Wed Mar 16, 3:05PM CDT
Antibodies bind specifically to misfolded, non-native forms of transthyretin, disrupting fibril formation
PRTA: 38.17 (-1.03)
Prothena Q4 Loss Narrower than Expected, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Fri Feb 19, 10:06AM CST
Prothena (PRTA) reported a loss of 76 cents per share in the fourth-quarter of 2015 on revenues of $0.3 million.
PRTA: 38.17 (-1.03), ANIK: 50.27 (+0.10), CELG: 99.23 (+2.37)
Data From Prothena's Ongoing Phase 1/2 Clinical Trial of NEOD001 in AL Amyloidosis Published in the Journal of Clinical Oncology
Globe Newswire - Tue Feb 09, 7:10AM CST
Interim Results Previously Presented at Meetings of the American Society for Clinical Oncology and the European Hematology Association
PRTA: 38.17 (-1.03)
Prothena to Report Fourth Quarter and Full Year 2015 Financial Results and Host Webcast Conference Call on February 18
GlobeNewswire - Thu Feb 04, 3:06PM CST
Prothena Corporation plc (NasdaqRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today that it will report its fourth quarter and full year 2015 financial results on Thursday, February 18, 2016, after the close of the U.S. financial markets. The announcement will be followed by a live audio webcast and conference call at 4:30 PM ET.
PRTA: 38.17 (-1.03)
Prothena Reports Results of Phase 1 Single Ascending Dose Study of PRX003, Demonstrating Target Engagement of the Novel Anti-MCAM Antibody for Inflammatory Diseases
Globe Newswire - Thu Jun 09, 3:05PM CDT
- All doses of PRX003 found to be safe and well tolerated, meeting the primary objective of the Phase 1 single ascending dose study in healthy volunteers
PRTA: 38.17 (-1.03)
Prothena to Present Wide Range of Studies on Amyloidosis, Including New Clinical Data on NEOD001, at International Symposium on Amyloidosis
Globe Newswire - Mon May 23, 3:05PM CDT
- New clinical data to be presented from expansion cohort of Phase 1/2 trial of NEOD001 for the potential treatment of AL amyloidosis
PRTA: 38.17 (-1.03)
Prothena to Present Quality of Life Data on AL Amyloidosis at European Hematology Association 21st Congress
Globe Newswire - Thu May 19, 3:05PM CDT
DUBLIN, Ireland, May 19, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq
RTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that data from multiple quality of life studies in patients with AL amyloidosis will be highlighted at The European Hematology Association (EHA) 21st Congress to be held June 9-12 in Copenhagen, Denmark. PRTA: 38.17 (-1.03)
Prothena to Present Clinical Results From its Phase 1 Single Ascending Dose Study of PRX003, an Anti-MCAM Antibody Being Investigated for Inflammatory Diseases, at EULAR 2016
Globe Newswire - Mon May 09, 3:05PM CDT
DUBLIN, Ireland, May 09, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq
RTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that clinical data from its Phase 1 single ascending dose study of PRX003 in healthy volunteers will be highlighted in an oral presentation at The European League Against Rheumatism Annual European Congress of Rheumatology (EULAR 2016) to be held June 8-11 in London. PRTA: 38.17 (-1.03)
Prothena (PRTA) Reports Wider-than-Expected Loss in Q1
Zacks Equity Research - Zacks Investment Research - Wed May 04, 12:00PM CDT
Prothena Corporation plc (PRTA) reported a loss of 81 cents per share in the first quarter of 2016, much wider than both the Zacks Consensus Estimate of a loss of 70 cents.
SHPG: 175.38 (+0.76), PRTA: 38.17 (-1.03), NKTR: 15.09 (+0.11)
Prothena Reports First Quarter 2016 Financial Results and Provides R&D Update
Globe Newswire - Tue May 03, 3:05PM CDT
- Net cash used in operating and investing activities was $25.4 million in the first quarter; strong quarter-end cash position of $474.3 million, including net proceeds of $128.6 million raised through January 2016 public equity offering, supports advancement of multiple clinical development programs
PRTA: 38.17 (-1.03)
Drug Stocks Q1 Earnings Preview: AEGR, AERI, MACK, PRTA
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 8:04AM CDT
The going has been quite satisfactory as we stand in the thick of the first earnings season of the year.
MACK: 6.20 (-0.09), BIIB: 234.60 (+1.60), ABT: 38.74 (+1.01), JNJ: 116.46 (+0.28), AERI: 17.56 (-0.02), AEGR: 1.56 (+0.03), PRTA: 38.17 (-1.03)
Prothena (PRTA): What's Ahead for the Stock in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 5:42PM CDT
Prothena (PRTA) is expected to report first-quarter 2016 earnings on May 3.
ZTS: 47.33 (+0.04), AGIO: 47.07 (-0.26), PRTA: 38.17 (-1.03)
Data from Prothena's Preclinical Program on Conformation-Specific Antibodies Against Misfolded Transthyretin Published in Amyloid
Globe Newswire - Wed Mar 16, 3:05PM CDT
Antibodies bind specifically to misfolded, non-native forms of transthyretin, disrupting fibril formation
PRTA: 38.17 (-1.03)
Prothena Q4 Loss Narrower than Expected, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Fri Feb 19, 10:06AM CST
Prothena (PRTA) reported a loss of 76 cents per share in the fourth-quarter of 2015 on revenues of $0.3 million.
PRTA: 38.17 (-1.03), ANIK: 50.27 (+0.10), CELG: 99.23 (+2.37)
Data From Prothena's Ongoing Phase 1/2 Clinical Trial of NEOD001 in AL Amyloidosis Published in the Journal of Clinical Oncology
Globe Newswire - Tue Feb 09, 7:10AM CST
Interim Results Previously Presented at Meetings of the American Society for Clinical Oncology and the European Hematology Association
PRTA: 38.17 (-1.03)
Prothena to Report Fourth Quarter and Full Year 2015 Financial Results and Host Webcast Conference Call on February 18
GlobeNewswire - Thu Feb 04, 3:06PM CST
Prothena Corporation plc (Nasdaq
RTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today that it will report its fourth quarter and full year 2015 financial results on Thursday, February 18, 2016, after the close of the U.S. financial markets. The announcement will be followed by a live audio webcast and conference call at 4:30 PM ET. PRTA: 38.17 (-1.03)
